Neuropathies associated with monoclonal gammopathies

Area of Science:

• Neurology
• Hematology
• Immunology

Background:

• Idiopathic peripheral neuropathy affects numerous patients, with a significant subset exhibiting serum monoclonal gammopathy (M-protein).
• The incidence of M-proteins in these patients is notably higher (approximately 10%) compared to the general population.
• A subset (5%) of these cases are linked to identifiable plasma cell dyscrasias, necessitating specific diagnostic and therapeutic considerations.

Purpose of the Study:

• To review the current understanding of monoclonal gammopathy associated with peripheral neuropathy.
• To highlight the clinical significance of recognizing M-proteins in neurological disorders.
• To discuss the pathophysiological mechanisms and diagnostic challenges in these conditions.

Main Methods:

• Literature review of studies investigating monoclonal gammopathy in peripheral neuropathy.
• Analysis of the association between M-proteins and various plasma cell dyscrasias.
• Examination of pathophysiological mechanisms, including antibody activity against myelin-associated glycoprotein.

Main Results:

• M-protein is found in about 10% of idiopathic peripheral neuropathy cases, six times the general population rate.
• Sclerotic myeloma and primary systemic amyloidosis are key conditions where M-protein presence impacts neuropathy.
• Monoclonal gammopathy of undetermined significance (MGUS) neuropathy pathophysiology remains poorly understood, with potential M-protein antibody activity implicated.

Conclusions:

• Monoclonal gammopathy is a significant finding in peripheral neuropathy, requiring careful evaluation for underlying plasma cell dyscrasias.
• Early recognition of conditions like sclerotic myeloma can lead to improved neuropathy outcomes.
• Further research is needed to elucidate the mechanisms of neuropathy in MGUS.